{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:15:44Z","timestamp":1774404944110,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":298,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The 2020 American Association of Clinical Endocrinologists guidelines for assessing osteoporosis among postmenopausal women stratified postmenopausal women with osteoporosis to \u201chigh\u201d and \u201cvery-high\u201d fracture risk categories and recommended anabolic agents as initial therapy followed by an antiresorptive agent. Switching the order can blunt the effect of anabolic agents, and failing to follow with an antiresorptive can lead to loss of bone generated by the anabolic agent. It would be helpful to understand the real-world prescribing patterns of anabolic agents. Using the 2010\u20132015 Medicare 100% osteoporosis database, we assessed patient profiles, teriparatide prescribers, persistence of teriparatide therapy, and antiresorptive agent use after teriparatide discontinuation among elderly women who initiated teriparatide from 2011 to 2013. This study included 14,786 patients. In the year before teriparatide initiation, 30.0% of them had a fracture, 67.6% had a dual energy x-ray absorptiometry scan, 74.4% had a diagnosis of osteoporosis, and 47.9% used antiresorptive agents (non-na\u00efve teriparatide users). Among those who had fractures, 49.4% initiated teriparatide within 3\u2009months postfracture. Teriparatide was prescribed for 37% of users by primary care doctors, 19% by rheumatologists, 13% by endocrinologists, and 7.0% by orthopedists. Median time of teriparatide use was 7.2\u2009months. After teriparatide discontinuation, 40.8% switched to antiresorptive agents (31.9% among na\u00efve teriparatide users, 50.5% among non-na\u00efve users). Among switchers, 42.5% switched within 60\u2009days, 50.5% switched to denosumab, and 31.6% switched to oral bisphosphonates. This study of real-world prescribing data found that about half of teriparatide users switched from an antiresorptive agent, and less than half switched to antiresorptive agents after teriparatide discontinuation. Persistence of teriparatide use was suboptimal. In the management of postmenopausal osteoporosis, increasing the persistence of teriparatide use and improving the appropriate treatment sequence of anabolic and antiresorptive drugs are critical to maximizing gains in bone mass, providing the greatest protection against fractures. \u00a9 2021 American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4439","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T06:01:09Z","timestamp":1630994469000},"page":"2309-2316","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2460-9542","authenticated-orcid":false,"given":"Jiannong","family":"Liu","sequence":"first","affiliation":[{"name":"Chronic Disease Research Group Hennepin Healthcare Research Institute Minneapolis MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Laster","sequence":"additional","affiliation":[{"name":"Arthritis & Osteoporosis Consultants of the Carolinas Charlotte NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Xu","sequence":"additional","affiliation":[{"name":"Amgen Inc Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Guo","sequence":"additional","affiliation":[{"name":"Chronic Disease Research Group Hennepin Healthcare Research Institute Minneapolis MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Oates","sequence":"additional","affiliation":[{"name":"Amgen Inc Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shravanthi R.","family":"Gandra","sequence":"additional","affiliation":[{"name":"Amgen Inc Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"issue":"5","key":"2024012713454463500_jbmr4439-bib-0001","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4158\/GL-2020-0524","article-title":"American Association of Clinical Endocrinologists Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"9999","key":"2024012713454463500_jbmr4439-bib-0002","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"10117","key":"2024012713454463500_jbmr4439-bib-0003","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"2024012713454463500_jbmr4439-bib-0004","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2024012713454463500_jbmr4439-bib-0005","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Guideline Update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012713454463500_jbmr4439-bib-0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"issue":"5","key":"2024012713454463500_jbmr4439-bib-0007","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"2024012713454463500_jbmr4439-bib-0008","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/jc.2008-2630","article-title":"Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis","volume":"94","author":"Leder","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012713454463500_jbmr4439-bib-0009","author":"Cosman"},{"issue":"5","key":"2024012713454463500_jbmr4439-bib-0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024012713454463500_jbmr4439-bib-0011","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024012713454463500_jbmr4439-bib-0012","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jbm4.10041","article-title":"Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy","volume":"2","author":"Leder","year":"2018","journal-title":"JBMR Plus"},{"issue":"11","key":"2024012713454463500_jbmr4439-bib-0013","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00198-018-4630-6","article-title":"Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis","volume":"29","author":"Liu","year":"2018","journal-title":"Osteoporos Int"},{"key":"2024012713454463500_jbmr4439-bib-0014","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/106286069901400607","article-title":"Identifying persons with diabetes using Medicare claims data","volume":"14","author":"Hebert","year":"1999","journal-title":"Am J Med Qual"},{"issue":"1","key":"2024012713454463500_jbmr4439-bib-0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"issue":"1","key":"2024012713454463500_jbmr4439-bib-0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","article-title":"Risk of subsequent fracture after prior fracture among older women","volume":"30","author":"Balasubramanian","year":"2019","journal-title":"Osteoporos Int"},{"issue":"8","key":"2024012713454463500_jbmr4439-bib-0017","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00198-018-4502-0","article-title":"Characteristics of recurrent fractures","volume":"29","author":"Kanis","year":"2018","journal-title":"Osteoporos Int"},{"issue":"19","key":"2024012713454463500_jbmr4439-bib-0018","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"2024012713454463500_jbmr4439-bib-0019","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11657-018-0466-0","article-title":"Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis","volume":"13","author":"Usui","year":"2018","journal-title":"Arch Osteoporos"},{"issue":"9","key":"2024012713454463500_jbmr4439-bib-0020","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s00198-016-3611-x","article-title":"Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database","volume":"27","author":"Chan","year":"2016","journal-title":"Osteoporos Int"},{"key":"2024012713454463500_jbmr4439-bib-0021","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00198-013-2284-y","article-title":"The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results","volume":"24","author":"Silverman","year":"2013","journal-title":"Osteoporos Int"},{"key":"2024012713454463500_jbmr4439-bib-0022","doi-asserted-by":"crossref","first-page":"314970","DOI":"10.4061\/2011\/314970","article-title":"Factors associated with persistence with teriparatide therapy: results from the DANCE observational study","volume":"2011","author":"Gold","year":"2011","journal-title":"J Osteoporos"},{"key":"2024012713454463500_jbmr4439-bib-0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CIA.S97593","article-title":"Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates","volume":"11","author":"Gu","year":"2016","journal-title":"Clin Interv Aging"},{"issue":"11","key":"2024012713454463500_jbmr4439-bib-0024","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4439","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/12\/2309\/55453525\/jbmr4439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/36\/12\/2309\/55453525\/jbmr4439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:08:02Z","timestamp":1710328082000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/36\/12\/2309-2316\/7516470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,9,7]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4439","relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JBMR.4439\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4439\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4439\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4439\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4439\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4439\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JBMR.4439\/v2\/review2","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2021-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}